Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy

被引:88
作者
Roldan, Vanessa [2 ,3 ]
Marin, Francisco [1 ,3 ,4 ]
Gimeno, Juan R. [1 ,3 ]
Ruiz-Espejo, Francisco [3 ,5 ]
Gonzalez, Josefa [1 ]
Feliu, Eloisa [6 ]
Garcia-Honrubia, Antonio [4 ]
Saura, Daniel [1 ]
de la Morena, Gonzalo [1 ]
Valdes, Mariano [1 ]
Vicente, Vicente [2 ,3 ]
机构
[1] Hosp Univ Virgen Arrixaca, Dept Cardiol, Murcia 30120, Spain
[2] Univ Murcia, Ctr Reg Hemodonac, Murcia, Spain
[3] Inst Salud Carlos III, Red Invest Cardiovasc RECAVA, Madrid, Spain
[4] Hosp Gen Univ, Dept Cardiol, Alicante, Spain
[5] Hosp Univ Virgen Arrixaca, Dept Clin Anal, Murcia 30120, Spain
[6] Hosp Gen Univ, Magnet Resonance Unit, Alicante, Spain
关键词
D O I
10.1016/j.ahj.2008.01.035
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background Hypertrophic cardiomyopathy (HCM) is defined by the presence of unexplained left ventricular hypertrophy, myocyte disarray, and interstitial fibrosis. An increase in extracellular matrix produces interstitial fibrosis, by raised amounts of collagen type I/III. Regions of myocardial late gadolinium enhancement by cardiac magnetic resonance (CMR) represented increased myocardial collagen. Regarding the role of matrix metalloproteinases (MMPs) in myocardial remodeling and subsequent fibrosis, the aim of our study was to explore the relation between MMP system and myocardial late gadolinium enhancement by CMR (as expression of image-documented fibrosis) and N-terminal pro-brain natriuretic peptide (NT-proBNP) (as a marker of cardiac overload) in HCM. Methods We included 67 HCM patients (44 men aged 49 14 years) and were compared to 58 controls with similar age and sex. Risk factors for sudden death were recorded. A blinded CMR was performed with gadolinium. Matrix metalloproteinase 1, MMP-2, and MMP-9 plasma levels were assayed by enzyme-linked immunosorbent assay. Serum samples were used for measurement of NT-proBNP. Results In patients, >50% of MMP-1 values were below the lowest limit of detection of the technique. Raised levels of MMP-2, MMP-9, and NT-proBNP were observed in HCM patients (all P < .01). Matrix metalloproteinase 2 was associated with dyspnea (P = .049) and correlated with MMP-9 (r = 0.28, P =.025) and NT-proBNP (r = 0.39, P = .001). Matrix metalloproteinase 9 was associated with the presence of gadolinium enhancement in CMR (P = .001) and correlated with NT-proBNP (r = 0.52, P < .001). NT-proBNP was also associated with gadolinium enhancement (P = .006). Both MMP-2 and MMP-9 correlated negatively with exercise capacity (metabolic equivalent units), (r = -0.36 and r = -0.42 respectively, both P < .01). On multivariate analysis (adjusted by sudden death risk factors and echocardiographic markers), only MMP-9 was associated with fibrosis (P = .011). Conclusions Matrix metalloproteinase 9 is independently associated with gadolinium enhancement on CMR in patients with hypertrophic cardiomyopathy, suggesting that the MMP system has an important role in cardiac remodeling and fibrosis in this condition.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 33 条
[1]
Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy [J].
Briguori, C ;
Betocchi, S ;
Manganelli, F ;
Gigante, B ;
Losi, MA ;
Ciampi, Q ;
Gottilla, R ;
Violante, A ;
Tocchetti, CG ;
Volpe, M ;
Chiariello, M .
EUROPEAN HEART JOURNAL, 2001, 22 (15) :1328-1336
[2]
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction [J].
Ducharme, A ;
Frantz, S ;
Aikawa, M ;
Rabkin, E ;
Lindsey, M ;
Rohde, LE ;
Schoen, FJ ;
Kelly, RA ;
Werb, Z ;
Libby, P ;
Lee, RT .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (01) :55-62
[3]
Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy [J].
Dumont, Carlos A. ;
Monserrat, Lorenzo ;
Soler, Rafaela ;
Rodriguez, Esther ;
Fernandez, Xusto ;
Peteiro, Jess ;
Bouzas, Beatriz ;
Pinon, Pablo ;
Castro-Beiras, Alfonso .
REVISTA ESPANOLA DE CARDIOLOGIA, 2007, 60 (01) :15-23
[4]
Hypertrophic cardiomyopathy [J].
Elliott, P ;
McKenna, WJ .
LANCET, 2004, 363 (9424) :1881-1891
[5]
Elevated serum markers for collagen synthesis in patients with hypertrophic cardiornyopathy and diastolic dysfunction [J].
Fassbach, M ;
Schwartzkopff, B .
ZEITSCHRIFT FUR KARDIOLOGIE, 2005, 94 (05) :328-335
[6]
Risk mechanisms in hypertensive heart disease [J].
Frohlich, ED .
HYPERTENSION, 1999, 34 (04) :782-789
[7]
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice [J].
Heymans, S ;
Lupu, F ;
Terclavers, S ;
Vanwetswinkel, B ;
Herbert, JM ;
Baker, A ;
Collen, D ;
Carmeliet, P ;
Moons, L .
AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (01) :15-25
[8]
FIBRILLAR COLLAGEN AND MYOCARDIAL STIFFNESS IN THE INTACT HYPERTROPHIED RAT LEFT-VENTRICLE [J].
JALIL, JE ;
DOERING, CW ;
JANICKI, JS ;
PICK, R ;
SHROFF, SG ;
WEBER, KT .
CIRCULATION RESEARCH, 1989, 64 (06) :1041-1050
[9]
Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure:: relation to functional data and prognosis [J].
Jordan, A. ;
Roldan, V. ;
Garcia, M. ;
Monmeneu, I. ;
de Burgos, F. G. ;
Lip, G. Y. H. ;
Marin, F. .
JOURNAL OF INTERNAL MEDICINE, 2007, 262 (03) :385-392
[10]
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT [J].
Latini, R ;
Masson, S ;
Anand, I ;
Salio, M ;
Hester, A ;
Judd, D ;
Barlera, S ;
Maggioni, AP ;
Tognoni, G ;
Cohn, JN .
EUROPEAN HEART JOURNAL, 2004, 25 (04) :292-299